These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 6867236)

  • 1. A rating scale for tardive dyskinesia and Parkinsonian symptoms.
    Smith RC; Allen R; Gordon J; Wolff J
    Psychopharmacol Bull; 1983; 19(2):266-76. PubMed ID: 6867236
    [No Abstract]   [Full Text] [Related]  

  • 2. Current views on tardive dyskinesia.
    Gerlach J
    Pharmacopsychiatry; 1991 Mar; 24(2):47-8. PubMed ID: 1852791
    [No Abstract]   [Full Text] [Related]  

  • 3. Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors.
    Guigoni C; Aubert I; Li Q; Gurevich VV; Benovic JL; Ferry S; Mach U; Stark H; Leriche L; Håkansson K; Bioulac BH; Gross CE; Sokoloff P; Fisone G; Gurevich EV; Bloch B; Bezard E
    Parkinsonism Relat Disord; 2005 Jun; 11 Suppl 1():S25-9. PubMed ID: 15885624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of levetiracetam in Parkinson disease patients with levodopa-induced dyskinesia.
    Lyons KE; Pahwa R
    Clin Neuropharmacol; 2006; 29(3):148-53. PubMed ID: 16772814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration.
    Carlsson T; Carta M; Muñoz A; Mattsson B; Winkler C; Kirik D; Björklund A
    Brain; 2009 Feb; 132(Pt 2):319-35. PubMed ID: 19039008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Unified Dyskinesia Rating Scale: presentation and clinimetric profile.
    Goetz CG; Nutt JG; Stebbins GT
    Mov Disord; 2008 Dec; 23(16):2398-403. PubMed ID: 19025759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blink rates in parkinsonism.
    Karson CN; LeWitt PA; Calne DB; Wyatt RJ
    Ann Neurol; 1982 Dec; 12(6):580-3. PubMed ID: 7159063
    [No Abstract]   [Full Text] [Related]  

  • 8. Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study.
    da Silva-Júnior FP; Braga-Neto P; Sueli Monte F; de Bruin VM
    Parkinsonism Relat Disord; 2005 Nov; 11(7):449-52. PubMed ID: 16154788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- exposed monkeys.
    Blanchet P; Bédard PJ; Britton DR; Kebabian JW
    J Pharmacol Exp Ther; 1993 Oct; 267(1):275-9. PubMed ID: 7901395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacology of levodopa-induced dyskinesia in parkinsonian patients.
    Rascol O; Brefel-Courbon C; Descombes S; Montastruc JL
    Adv Neurol; 1999; 80():485-90. PubMed ID: 10410760
    [No Abstract]   [Full Text] [Related]  

  • 11. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies.
    Bezard E; Brotchie JM; Gross CE
    Nat Rev Neurosci; 2001 Aug; 2(8):577-88. PubMed ID: 11484001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Rush dyskinesia scale or Goetz scale].
    Krystkowiak P; Defebvre L
    Rev Neurol (Paris); 2002 May; 158(5 Pt 1):622-4. PubMed ID: 12072837
    [No Abstract]   [Full Text] [Related]  

  • 13. Pathophysiology of motor complications in Parkinson disease: postsynaptic mechanisms are crucial.
    Linazasoro G
    Arch Neurol; 2007 Jan; 64(1):137-40. PubMed ID: 17210824
    [No Abstract]   [Full Text] [Related]  

  • 14. New insights in Parkinson's disease therapy: can levodopa-induced dyskinesia ever be manageable.
    Hadj Tahar A; Grondin R; Grégoire L; Calon F; Di Paolo T; Bédard PJ
    Adv Neurol; 2003; 91():51-64. PubMed ID: 12442663
    [No Abstract]   [Full Text] [Related]  

  • 15. No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients.
    Silver H; Geraisy N; Schwartz M
    J Clin Psychiatry; 1995 Apr; 56(4):167-70. PubMed ID: 7713856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias.
    Carta M; Carlsson T; Muñoz A; Kirik D; Björklund A
    Prog Brain Res; 2008; 172():465-78. PubMed ID: 18772046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The neural mechanisms underlying levodopa-induced dyskinesia in Parkinson's disease.
    Brotchie JM
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S105-12; discussion S112-4. PubMed ID: 10762137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tardive dyskinesia and impaired glucose tolerance.
    Chong SA; Mythily ; Lum A; Huak CY; Kane J
    Hum Psychopharmacol; 2002 Aug; 17(6):305-7. PubMed ID: 12404676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. End-of-dose wearing off in Parkinson disease: a 9-question survey assessment.
    Stacy M; Hauser R; Oertel W; Schapira A; Sethi K; Stocchi F; Tolosa E
    Clin Neuropharmacol; 2006; 29(6):312-21. PubMed ID: 17095894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of advanced Parkinson's disease by posterior GPi pallidotomy: 1-year results of a pilot study.
    Baron MS; Vitek JL; Bakay RA; Green J; Kaneoke Y; Hashimoto T; Turner RS; Woodard JL; Cole SA; McDonald WM; DeLong MR
    Ann Neurol; 1996 Sep; 40(3):355-66. PubMed ID: 8797525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.